FBRX
Forte Biosciences Inc

2,995
Mkt Cap
$234.38M
Volume
280,812.00
52W High
$28.68
52W Low
$4.90
PE Ratio
-4.21
FBRX Fundamentals
Price
$20.21
Prev Close
$18.71
Open
$19.75
50D MA
$13.48
Beta
0.58
Avg. Volume
96,801.00
EPS (Annual)
-$12.17
P/B
2.79
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Forte Biosciences (NASDAQ:FBRX) Posts Quarterly Earnings Results, Beats Expectations By $0.05 EPS
Forte Biosciences (NASDAQ:FBRX - Get Free Report) posted its earnings results on Friday. The company reported ($0.99) earnings per share for the quarter, topping the consensus estimate of ($1.04) by...
MarketBeat·4d ago
News Placeholder
More News
News Placeholder
Forte Biosciences (NASDAQ:FBRX) Downgraded to Sell Rating by Wall Street Zen
Wall Street Zen lowered shares of Forte Biosciences from a "hold" rating to a "sell" rating in a research note on Saturday...
MarketBeat·5d ago
News Placeholder
Forte Biosciences, Inc. Announces Third Quarter 2025 Results and Provides Update
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced its third quarter 2025...
Business Wire·6d ago
News Placeholder
Forte Biosciences, Inc. to Present at Upcoming Healthcare Conferences
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, will be presenting at 3 upcoming...
Business Wire·17d ago
News Placeholder
Forte Biosciences, Inc. to Present at Upcoming Investor Meetings
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced it will be presenting at...
Business Wire·10mo ago
News Placeholder
Forte Biosciences to Host RandD Day December 3, 2024
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced it will host an R&D Day...
Business Wire·1y ago
News Placeholder
5 Stocks Retail Investors Are Most Bullish On At Mid-Day
Retailers went overboard about a couple of biotech stocks and a MedTech name, among others on Wednesday.
Stocktwits·1y ago
News Placeholder
Forte Biosciences Stock More Than Doubles On Oversubscribed $53M Private Placement: Retail Goes Wild
The funds will support clinical development of FB102, Forte’s proprietary anti-CD122 monoclonal antibody targeting autoimmune and autoimmune-related diseases.
Stocktwits·1y ago
News Placeholder
Forte Biosciences, Inc. Announces Oversubscribed $53 Million Private Placement From Leading Healthcare Institutional Investors to Advance FB102 Across Autoimmune Indications
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced an oversubscribed $53...
Business Wire·1y ago
News Placeholder
Forte Biosciences, Inc. Announces Third Quarter 2024 Results and Provides Business Update
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced third quarter 2024...
Business Wire·1y ago

Latest FBRX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.